On Thursday 25, the general session IDIVAL within the framework of the general sessions Valdecilla, the Doctor Pascual Sanchez , a neurologist at the Hospital Valdecilla and researcher IDIVAL gave way after his presentation, the prestigious and neurologist Bruce Miller .
Bruce Miller is a world leader in the study and treatment of dementias. He is Professor of Neurology at the University of California San Francisco (USA), and clinical director of the Memory and Aging Center, where they work about 200 professionals. It is also the principal investigator of the Alzheimer's Disease Reseach Center and is part of several international research consortia. Miller has received the Potamkin Raymond Adams of the American Association of Neurology Elliot Royer Award of the community of San Francisco Award from the American Academy of Neurology.
His domain area, which is a global reference for their contributions, is behavioral neurology being the focus of their research, the relationship between behavioral disorders and genetic and molecular basis of disease especially in the frontotemporal dementias ..
His research highlights the search for biomarkers to refine diagnosis and precisely target the treatment of Alzheimer's disease. The Dr Pascual Sanchez , integrated Unit cognitive impairment, the group has collaborated with Miller analyzing the impact of one of these new biomarkers, PET-PIB, in the clinical management of the patient. His work was published in the prestigious journal "Neurology."
Dementias are a major social and health challenges that our societies face. These diseases currently affect more than 36 million people and is expected that this number will double every 20 years if there are no effective interventions. that public health actions aimed at reducing cerebrovascular risk factors and changing lifestyles could prevent 20% of new cases of dementia in 20 years is estimated. However, today no there are global initiatives to take on these challenges.
Dr. Miller is co-IP Global Brain Health Initiative (GBHI). the GBHI is a project that starts off this year, worth 177 million dollars, in order to promote formation of regional leaders in southern Europe and Latin America in the field of dementias. This is to provide the necessary tools through various training programs, to generate a positive impact on the care of patients with dementia in their respective countries.
THE GLOBAL BRAIN HEALTH INSTITUTE
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Es incuestionable la influencia negativa del consumo de fructosa sobre...
